Cortexyme, Inc. (CRTX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cortexyme, Inc. (CRTX) trades at $1.95 with AI Score 44/100 (Grade C). Cortexyme, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's and other degenerative diseases. Market cap: $70.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for CRTX: CRTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CRTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CRTX: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cortexyme, Inc. (CRTX) Healthcare & Pipeline Overview
Cortexyme, Inc. is a clinical-stage biopharmaceutical company specializing in therapeutics for Alzheimer's and degenerative diseases. Their lead drug candidate, atuzaginstat (COR388), a gingipain inhibitor, is in Phase II/III trials, positioning them within the competitive biotechnology sector focused on neurological disorders.
What Is the Investment Thesis for CRTX?
Cortexyme's investment thesis centers on the potential of atuzaginstat (COR388) to address Alzheimer's disease by targeting gingipains. The Phase II/III clinical trial results will be a key catalyst. Positive data could drive significant value, while negative results pose a substantial risk. The company's focus on a novel mechanism of action differentiates it from other Alzheimer's drug developers. The current market capitalization of $70.5M reflects the high-risk, high-reward nature of clinical-stage biotech investments. Success in other indications like oral squamous cell carcinoma and periodontitis could provide additional upside. Investors should closely monitor clinical trial outcomes and regulatory developments.
Based on FMP financials and quantitative analysis
CRTX Key Highlights
Lead drug candidate atuzaginstat (COR388) is in Phase II/III clinical trials for Alzheimer's disease.
- Cortexyme is exploring atuzaginstat's potential in treating oral squamous cell carcinoma, periodontitis, and coronavirus infection.
- The company was incorporated in 2012 and is headquartered in South San Francisco, California.
- Cortexyme has 55 employees.
- The company's market capitalization is $0.07 billion.
Who Are CRTX's Competitors?
CRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.30 | -3.37% | $627M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CRTX's Key Strengths?
Novel approach targeting gingipains in Alzheimer's disease.
- Lead drug candidate in Phase II/III clinical trials.
- Potential applications in multiple indications.
- Experienced management team.
What Are CRTX's Weaknesses?
Clinical-stage company with no approved products.
- High reliance on the success of atuzaginstat.
- Limited financial resources.
- Small number of employees.
What Could Drive CRTX Stock Higher?
Announcement of Phase II/III clinical trial results for atuzaginstat in Alzheimer's disease.
- Initiation of clinical trials for atuzaginstat in oral squamous cell carcinoma and periodontitis.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Publication of research findings in peer-reviewed journals.
What Are the Key Risks for CRTX?
Financial-distress signal — its Altman Z-Score of -3.11 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for atuzaginstat.
- Regulatory delays or rejection.
- Competition from other Alzheimer's drug developers.
- Limited financial resources.
- Dependence on key personnel.
What Are the Growth Opportunities for CRTX?
- Growth opportunity 1: Successful completion of the Phase II/III clinical trial for atuzaginstat in Alzheimer's disease represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, capturing a portion of the multi-billion dollar Alzheimer's market. The timeline for potential FDA approval is estimated to be 2-3 years following successful trial completion. Cortexyme's competitive advantage lies in its novel mechanism of action targeting gingipains.
- Growth opportunity 2: Expansion of atuzaginstat's application to other indications, such as oral squamous cell carcinoma and periodontitis, offers additional growth potential. These markets, while smaller than Alzheimer's, still represent significant commercial opportunities. Clinical trials in these areas could provide valuable data and potentially lead to new revenue streams. The timeline for these indications is dependent on the progress of ongoing research and clinical trials. Cortexyme's expertise in gingipain inhibition provides a competitive edge.
- Growth opportunity 3: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of atuzaginstat. Collaborations could provide access to additional funding, expertise, and distribution channels. The timeline for potential partnerships is uncertain, but could occur at any stage of development. Cortexyme's unique technology and promising clinical data make it an attractive partner.
- Growth opportunity 4: Development of a pipeline of additional drug candidates targeting other aspects of Alzheimer's disease and related disorders could diversify Cortexyme's portfolio and reduce its reliance on atuzaginstat. This would require significant investment in research and development, but could create long-term value. The timeline for new drug candidate development is typically several years. Cortexyme's expertise in neurodegenerative diseases provides a foundation for pipeline expansion.
- Growth opportunity 5: Securing additional funding through grants, venture capital, or public offerings is crucial for supporting Cortexyme's ongoing research and clinical trials. Access to capital will enable the company to advance its pipeline and pursue its growth strategies. The timeline for securing funding is dependent on market conditions and company performance. A strong track record of clinical progress will enhance Cortexyme's ability to attract investment.
What Are CRTX's Competitive Advantages?
- Proprietary gingipain inhibition technology.
- Patent protection for atuzaginstat (COR388).
- Clinical data supporting the efficacy of their drug candidates.
- Expertise in neurodegenerative diseases.
What Does CRTX Do?
Cortexyme, Inc., founded in 2012 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for Alzheimer's disease and other degenerative conditions. The company's primary focus is on addressing the underlying causes of these diseases through targeted therapeutics. Cortexyme's lead drug candidate, atuzaginstat (COR388), is an orally administered, brain-penetrating small molecule designed to inhibit gingipains, toxic proteases produced by the bacterium Porphyromonas gingivalis, which has been implicated in the pathogenesis of Alzheimer's disease. Atuzaginstat is currently undergoing Phase II/III clinical trials for patients with mild to moderate Alzheimer's. In addition to its Alzheimer's program, Cortexyme is exploring the potential of atuzaginstat in treating other conditions, including oral squamous cell carcinoma, periodontitis, and coronavirus infection, showcasing the broad applicability of its gingipain inhibition technology. With a team of 55 employees, Cortexyme is committed to advancing its pipeline and addressing significant unmet medical needs in the field of degenerative diseases.
What Products and Services Does CRTX Offer?
- Develop therapeutics for Alzheimer's disease and other degenerative diseases.
- Focus on inhibiting gingipains, toxic proteases implicated in Alzheimer's pathogenesis.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Research and develop new treatments for oral squamous cell carcinoma and periodontitis.
- Explore the potential of their lead drug candidate, atuzaginstat (COR388), in various indications.
- Advance their pipeline through preclinical and clinical development stages.
How Does CRTX Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of approved drugs.
- Out-license or partner with other companies for drug development and commercialization.
- Secure funding through grants, venture capital, and public offerings.
What Industry Does CRTX Operate In?
Cortexyme operates within the biotechnology industry, specifically targeting the Alzheimer's disease market. This market is characterized by a high unmet need and significant investment in research and development. The competitive landscape includes major pharmaceutical companies and smaller biotech firms, all vying to develop effective treatments for Alzheimer's. The aging global population is driving increased prevalence of Alzheimer's, fueling market growth. Cortexyme's focus on gingipain inhibition represents a novel approach compared to traditional amyloid-based therapies. The biotechnology industry is subject to stringent regulatory requirements and high clinical trial failure rates.
Who Are CRTX's Key Customers?
- Patients with Alzheimer's disease.
- Patients with oral squamous cell carcinoma.
- Patients with periodontitis.
- Healthcare providers who prescribe their drugs.
How Cortexyme, Inc. Is Valued
Cortexyme, Inc. carries a market capitalization of $70.5M, placing it in the micro-cap category. Relative to its peer group, CRTX's quantitative score of 44/100 is below the peer average of 76/100.
Company Profile
Cortexyme, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Casey Lynch. CRTX has traded publicly since 2019.
Financial Health
Cortexyme, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.11 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Cortexyme, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.1% above estimates on average.
CRTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Cortexyme's strategic direction, indicating a belief in future growth.
- Community sentiment has shifted positively, with discussions highlighting the potential of their innovative treatments in Alzheimer's research.
- Market perception is bolstered by recent partnerships that could enhance their research capabilities and product pipeline.
- Positive news coverage around breakthroughs in clinical trials has sparked interest among investors, driving enthusiasm for the stock.
Bear Case
- Concerns persist regarding the timeline for product commercialization, leading to skepticism about immediate revenue generation.
- Community discussions reveal a divide, with some investors wary of the competitive landscape in the biotech sector.
- Recent regulatory hurdles have raised questions about the pace of development, causing uncertainty among potential investors.
- Market sentiment remains cautious, with lingering doubts about the company's long-term viability amidst fluctuating trial results.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CRTX Latest News
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 6, 2022
CRTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRTX.
Price Targets
Wall Street price target analysis for CRTX.
CRTX MoonshotScore
What does this score mean?
The MoonshotScore rates CRTX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Casey Lynch
CEO
Casey Lynch serves as the CEO of Cortexyme, Inc., bringing extensive experience in the biotechnology and pharmaceutical industries. Her background includes leadership roles in drug development, clinical research, and corporate strategy. She has a proven track record of advancing innovative therapies through the clinical development process. Her expertise spans various therapeutic areas, including neurodegenerative diseases. She is responsible for guiding Cortexyme's strategic direction and overseeing its day-to-day operations.
Track Record: Under Casey Lynch's leadership, Cortexyme has advanced atuzaginstat (COR388) into Phase II/III clinical trials for Alzheimer's disease. She has overseen the expansion of the company's pipeline and the exploration of new indications for atuzaginstat. She has also been instrumental in securing funding to support the company's research and development efforts. Her strategic decisions have positioned Cortexyme as a leader in the field of gingipain inhibition.
Cortexyme, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for CRTX?
CRTX holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Cortexyme, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's and other degenerative diseases. Their lead drug candidate, atuzaginstat (COR388) …
What does Cortexyme, Inc. do?
Cortexyme, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease and other degenerative conditions. Their primary focus is on atuzaginstat (COR388), an orally administered gingipain inhibitor currently in Phase II/III clinical trials for mild to moderate Alzheimer's.
What do analysts say about CRTX stock?
Given Cortexyme's clinical-stage status and focus on a high-risk, high-reward therapeutic area like Alzheimer's disease, analyst opinions are likely to be highly sensitive to clinical trial data and regulatory developments. Valuation metrics would heavily rely on the potential success of atuzaginstat (COR388) and its market potential.
What are the main risks for CRTX?
The primary risk for Cortexyme lies in the potential failure of its Phase II/III clinical trial for atuzaginstat in Alzheimer's disease. Clinical trial failures are common in the biotechnology industry, particularly in Alzheimer's research. Regulatory hurdles and delays also pose a significant risk. Competition from other companies developing Alzheimer's treatments could limit Cortexyme's market share.
What are the key factors to evaluate for CRTX?
Cortexyme, Inc. (CRTX) holds an AI score of 44/100 (low). Cortexyme's investment thesis centers on the potential of atuzaginstat (COR388) to address Alzheimer's disease by targeting gingipains. Not financial advice.
How frequently does CRTX data refresh on this page?
CRTX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CRTX's recent stock price performance?
Cortexyme, Inc. (CRTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach targeting gingipains in Alzheimer's disease. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRTX overvalued or undervalued right now?
Cortexyme, Inc. (CRTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CRTX before investing?
Before investing in Cortexyme, Inc. (CRTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain.